Efficacy and Safety of a New Basal Insulin with a Bolus Boost (IDegAsp) Used Once Daily in Combination with Insulin Aspart (IAsp) in People with Type 1 Diabetes

被引：0
|
作者：
Hirsch, Irl B.
Franek, Edward
Courreges, Jean-Pierre
Mersebach, Henriette
Dykiel, Patrik
Bode, Bruce W.
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1064-P
引用
收藏
页码：A292 / A292
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety comparison of once daily basal insulin and twice daily premixed insulin in combination with oral antidiabetic agents (OAD) in type 2 diabetes (T2DM)
    Yang, Wenying
    Bu, Shi
    Guo, Xiaohui
    Lu, Guizhi
    Yang, Zhao-Jun
    Ren, Tingting
    Gao, Yan
    [J]. DIABETES, 2007, 56 : A554 - A554
  • [42] Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
    Jammah, Anwar Ali
    [J]. PRIMARY CARE DIABETES, 2021, 15 (01) : 132 - 137
  • [43] Safety and Effectiveness of Bolus Insulin Aspart in People with Type 2 Diabetes: A1chieve Sub-Analysis
    Hoosen Randeree
    Andreas Liebl
    Issam Hajjaji
    Mohammad Khamseh
    Lenita Zajdenverg
    Jian-Wen Chen
    Jihad Haddad
    [J]. Diabetes Therapy, 2013, 4 : 153 - 166
  • [44] Safety and Effectiveness of Bolus Insulin Aspart in People with Type 2 Diabetes: A1chieve Sub-Analysis
    Randeree, Hoosen
    Liebl, Andreas
    Hajjaji, Issam
    Khamseh, Mohammad
    Zajdenverg, Lenita
    Chen, Jian-Wen
    Haddad, Jihad
    [J]. DIABETES THERAPY, 2013, 4 (01) : 153 - 166
  • [45] Efficacy and Safety of Basal Insulin/GLP-1 Receptor Agonist Used in Combination for Type 2 Diabetes Management
    McCarty, Delilah
    Olenik, Alaina
    McCarty, Bryan P.
    [J]. JOURNAL OF PHARMACY PRACTICE, 2019, 32 (06) : 671 - 678
  • [46] Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
    Bode, Bruce W.
    Iotova, Violeta
    Kovarenko, Margarita
    Laffel, Lori M.
    Rao, Paturi V.
    Deenadayalan, Srikanth
    Ekelund, Magnus
    Larsen, Steffen Falgreen
    Danne, Thomas
    [J]. DIABETES CARE, 2019, 42 (07) : 1255 - 1262
  • [47] Once daily insulin glargine may induce loss of basal insulin action in some patients with type 1 diabetes receiving basal bolus regimens: The need for twice daily glargine?
    Idampitiya, C
    Ward, K
    Curtis, C
    Fernando, DJS
    Idris, I
    Thomson, G
    [J]. DIABETES, 2005, 54 : A493 - A493
  • [48] Biphasic insulin aspart given thrice-daily is as efficacious as a conventional basal bolus insulin regimen with four daily injections in subjects with type 2 diabetes
    Ligthelm, RJ
    Mouritzen, U
    Lynggaard, H
    Landin-Olsson, M
    Fox, C
    le Devehat, C
    Romero, E
    Liebl, A
    [J]. DIABETOLOGIA, 2005, 48 : A311 - A311
  • [49] Insulin aspart compared to regular insulin and insulin lispro in basal bolus therapy with NPH to treat pediatric patients with type 1 diabetes mellitus
    Arslanian, S
    Foster, C
    Wright, NM
    Stender, S
    Hales, P
    Hale, D
    [J]. DIABETOLOGIA, 2005, 48 : A327 - A327
  • [50] Comparison of insulin aspart, regular insulin, and insulin lispro in basal bolus therapy with NPH to treat pediatric patients with type 1 diabetes mellitus
    Arslanian, S
    Foster, C
    Wright, N
    Stender, S
    Hu, P
    Hale, P
    Hale, D
    [J]. DIABETES, 2005, 54 : A517 - A518
12345